trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim
Moderna and Pfizer COVID-19 vaccines utilize different lipid nanoparticle delivery mechanisms.
the verdict
SUPPORTED
the evidence backs this
refutedsupported
the weight of evidence
3 sources for · 0 against

Peer-reviewed literature and reference materials establish that the Moderna and Pfizer-BioNTech COVID-19 vaccines utilize different ionizable lipids within their lipid nanoparticle delivery systems, specifically employing SM-102 and ALC-0315 respectively.

Evidence for · 3
2025 · cited by 17
ConspectusThe clinical use of mRNA COVID-19 vaccines developed by Moderna and Pfizer-BioNTech has highlighted the critical role of ionizable lipid nanoparticles (LNPs) in the efficient loading, intracellular delivery, and cytoplasmic release of mRNAs. These LNPs typically comprise an ionizable lipid, a helper lipid, cholesterol, and a PEGylated-lipid, each contributing to the stability, structure, encapsulation efficiency, and nanoparticle-biology interactions of the final mRNA-LNPs both in vitro and in vivo. Notably, the ionizable amino-lipids, ALC-0315 used in the BioNTech/Pfizer vaccine and SM-102 in the Moderna vaccine, possess similar molecular structures, featuring multiple saturated aliphatic chains linked to a tertiary amine group via ester bonds. The acidification-induced ionization behavior of these amino-lipids is essential for enabling endosomal escape and facilitating the intracellular transfection of therapeutic mRNAs. However, despite their widespread clinical use, the physicochemical property-biological interaction and function relationships for LNPs remain poorly understood, particularly regarding how the internal nanostructural evolution during endosomal maturation influences mRNA release, endosomal escape, and gene expression. The rudimentary understanding continues to impede the rational design and optimization of RNA therapeutics.With long-standing expertise in amphiphile self-assembly and structural characterization, especially inverse lyotropic liquid crystalline mesophase-forming lipids, our group seeks to address this critical knowledge gap by establishing a clear connection between pH-triggered mesophase transitions and the biological performance of mRNA-LNPs, with the aim of providing new mechanistic insight into how the internal nanostructure affects mRNA delivery efficiency. This Account focuses on the pH-dependent inverse mesostructural behavior of ionizable LNPs containing two COVID-19 mRNA vaccine ionizable lipids, ALC-0315 and SM-102. We have applied high-throughput and cutting-edge time-resolved synchrotron radiation small-angle X-ray scattering (SAXS) to investigate both static and kinetic self-assembly and structural transitions of these ionizable LNPs without and with nucleic acid cargos (including mRNAs, polyA tails, and plasmid DNAs) upon acidification. We further explored the influence of other components in LNPs, such as select structure-forming helper lipids (monoolein and phytantriol) and cholesterol, on their physicochemical properties, mesophase behavior, and gene delivery performance. Notably, we correlated the mesophase transition of LNPs, from nonordered state to ordered inverse micellar, hexagonal, and cubic phases, with their mRNA transfection efficiency in macrophage cells, providing mechanistic insight into the role of internal nanostructure in endosomal escape and gene expression. Moreover, we addressed the impact of protein coronas formed upon exposure to biological environments, which can significantly alter the LNP internal structure and delivery efficiency. Our findings suggest that protein corona-modulated phase behavior of LNPs may contribute to reported inconsistency between in vitro and in vivo performance. Finally, we offer a perspective on future research trends in improving endosomal escape efficiency, promoting a passive nonendocytic cellular uptake pathway, modulating protein corona effects, monitoring the immune compatibility of PEG-free stabilizers, and leveraging of artificial intelligence approaches to accelerate formulation design and screening. Overall, this Account provides guidance for future mechanistic research with respect to LNP internal structures under various environmental and biological conditions, enabling the rational design of next-generation RNA therapeutics.
See more details
The analysis

rails:sufficiency:supported:for=2+1p:against=0+0p | v55:sufficiency

More for · 2
2021 · cited by 0
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the deadly disease known as coronavirus disease 2019 (COVID-19) that has reached pandemic proportions. Currently, there is no definitive treatment for COVID-19, although many vaccines have been developed. The World Health Organization has approved the safety and efficacy of the AstraZeneca/Oxford, Johnson and Johnson/Janssen (JnJ), Moderna, Pfizer/BioNTech, Sinopharm, and Sinovac vaccines so far. The approved formulations of AstraZeneca, JnJ, and Gam-COVID-vac (Sputnik V) contain DNA delivered within non-replicating recombinant adenovirus vector-based systems, while the Pfizer and Moderna vaccines utilize mRNA technology and lipid nanoparticle delivery systems. All of these vaccines encode production of the SARS-CoV-2 spike (S) protein, ultimately triggering immunity in the human body. COVID-19 causes several cardiovascular complications, such as arrhythmias, myocarditis, pericarditis, and venous thromboembolism. SARS-CoV-2 vaccines have been associated with rare, but sometimes fatal, cardiovascular side effects, which are the topics of this review. SARS-CoV-2 vaccines in general may cause thromboembolic events, such as cerebral vein thrombosis, and mRNA-based vaccines in particular may cause myocarditis/pericarditis, with the latter more likely to occur in younger adults after the second vaccination dose. Nevertheless, the advantages of these vaccines for ending the pandemic and/or decreasing the mo
cited by 0
The mechanism is the same as Moderna (above) except that composition of the lipid nanoparticles are different, with Pfizer using the ionizable lipid known Intracellular delivery is the process of introducing external materials into living cells. Materials that are delivered into cells include nucleic acids (DNA and RNA), proteins, peptides, impermeable small molecules, synthetic nanomaterials, organelles, and micron-scale tracers, devices and objects. Such molecules and materials can be used to investigate cellular behavior, engineer cell operations Pfizer-BioNTech COVID-19 Vaccine (branded as Comirnaty) designed to provide protection against COVID-19 caused by infection with the SARS-CoV-2 virus (US emergency use authorization 2020). The mechanism is the same as Moderna (above) except that composition of the lipid nanoparticles are different, with Pfizer using the ionizable lipid known as ALC-0315 while Moderna uses an ionizable lipid called SM-102. Antisense oligonucleotides (ASOs):
Everything we examined (3)
This check searched the claim as stated. It did not run a separate search for evidence against it.
  1. Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overviewpeer-reviewedno side taken
  2. Ionizable Lipid Nanoparticles for mRNA Delivery: Internal Self-Assembled Inverse Mesophase Structure and Endosomal Escape.peer-reviewedno side taken
  3. Intracellular deliveryreferenceno side taken
This receipt carries no identity, shared or not. Sharing publishes your connection to it, not your data.
Check your own claim
Challenge the receipt
trust me, bro: win the argument, pass the class, survive peer review.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt